Can sequencing immunotherapy before chemo boost stomach cancer outcomes?
NCT ID NCT04069273
First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether giving the immunotherapy drug pembrolizumab first, followed by a combination of ramucirumab and paclitaxel, can shrink tumors and delay progression in people with advanced gastric or gastroesophageal junction adenocarcinoma. The study enrolls about 58 adults with good performance status. Researchers are measuring response rates and side effects to see if this sequenced approach offers an advantage over standard treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a sequence of pembrolizumab (Keytruda) followed by ramucirumab (Cyramza) plus paclitaxel (Taxol)
- What this could lead to
- If successful, this sequenced immunotherapy approach could improve tumor shrinkage and delay disease progression in advanced gastric cancer.
- What could go wrong
- This is a small phase 2 trial, so results may not apply broadly. Combining multiple drugs also raises the risk of side effects like immune reactions or nerve damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Froedtert and The Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Mayo Clinic- Minnesota
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can surgery for stomach or esophageal cancer cloud the mind?